Carriers of the G2019 variant in LRRK2 and PRKN mutations showed sustained advantages in motor complications and activities of daily living, whereas GBA mutation carriers frequently developed cognitive impairment and stimulation-resistant symptoms within 2 to 7 years after surgical treatment. The gene discussed is GBA1; the disease is Cognitive impairment.